268. Nakajo-Nishimura syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 2 / Drugs : 3 - (DrugBank : 1) / Drug target genes : 2 - Drug target pathways : 37
Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
Baricitinib
Eli Lilly and Company
2020 Phase 2/Phase 3 NCT04517253 Japan
- Phase 2;Phase 3 EUCTR2025-000001-16-Outside-EU/EEA Japan
LY3009104
Eli Lilly and Company
- Phase 2;Phase 3 EUCTR2025-000001-16-Outside-EU/EEA Japan
Olumiant
Eli Lilly and Company
- Phase 2;Phase 3 EUCTR2025-000001-16-Outside-EU/EEA Japan
Eli Lilly and Company
2020 Phase 2/Phase 3 NCT04517253 Japan
- Phase 2;Phase 3 EUCTR2025-000001-16-Outside-EU/EEA Japan
LY3009104
Eli Lilly and Company
- Phase 2;Phase 3 EUCTR2025-000001-16-Outside-EU/EEA Japan
Olumiant
Eli Lilly and Company
- Phase 2;Phase 3 EUCTR2025-000001-16-Outside-EU/EEA Japan